Obesity is also believed to affect treatment response in PsA and AxSpA by inducing a chronic low-grade inflammatory state through inflammatory mediators such as TNF-alpha and interleukin-6 [42, 43]. The gene discussed is TNF; the disease is obesity due to melanocortin 4 receptor deficiency.